Finance

Lists
CONCORDBIO:NSE
Concord Biotech Ltd
₹1 384,10
+1,05%
(+14,40) 1D
14 Okt., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for CONCORDBIO...
Open
₹1 378,80
High
₹1 395,60
Low
₹1 372,10
Mkt. cap
144,80 mjd
Avg. vol.
143,66 k
Volume
63,72 k
Dividend
0,55%
Quarterly dividend
₹1,89
Ex-dividend date
24 Jul. 2026
P/E ratio
52,61
52-wk high
₹1 615,00
52-wk low
₹987,00
EPS
₹26,31
No. of employees
2 k
Open
₹1 378,80
High
₹1 395,60
Low
₹1 372,10
Mkt. cap
144,80 mjd
Avg. vol.
143,66 k
Volume
63,72 k
Dividend
0,55%
Quarterly dividend
₹1,89
Ex-dividend date
24 Jul. 2026
P/E ratio
52,61
52-wk high
₹1 615,00
52-wk low
₹987,00
EPS
₹26,31
No. of employees
2 k
News stories
From web sources and news partners
Profile
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients sold worldwide. It manufactures biopharmaceutical products across therapy segments such as immunosuppressant, oncology, antifungal, antibacterial and anthelmintic. It has two manufacturing facilities–at Dholka near Ahmedabad, which is approved by USFDA, and at Limbasi in Kheda district. Wikipedia
About Concord Biotech Ltd
CEO-
Employees1,62 k
Founded2000
Headquarters-
SectorPharmaceutical industry
Last report
03 Aug. 2026
Fiscal period
Q1 2027
₹5,52 / ₹5,60
-1,43%miss
Revenue / Est. (INR)
2,57 mjd / 2,45 mjd
+5,05%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,47 mjd
2,78 mjd
3,26 mjd
2,57 mjd
Cost of goods sold
775,44 m
941,71 m
1,32 mjd
890,11 m
Cost of revenue
775,44 m
941,71 m
1,32 mjd
890,11 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
444,56 m
467,81 m
477,71 m
436,38 m
Operating expense
994,14 m
1,03 mjd
837,11 m
1,04 mjd
Total operating expenses
1,77 mjd
1,98 mjd
2,16 mjd
1,93 mjd
Operating income
701,00 m
802,34 m
1,10 mjd
642,76 m
Other non operating income
133,52 m
99,76 m
-356,29 m
128,26 m
EBT including unusual items
856,84 m
861,56 m
1,14 mjd
783,43 m
EBT excluding unusual items
856,84 m
894,31 m
929,35 m
783,43 m
Income tax expense
226,21 m
225,14 m
256,08 m
206,46 m
Effective tax rate
26,40%
26,13%
22,45%
26,35%
Other operating expenses
365,67 m
378,34 m
163,96 m
424,64 m
Net income
635,81 m
644,77 m
887,90 m
585,26 m
Net profit margin
25,74%
23,21%
27,23%
22,73%
Earnings per share
6,03
6,31
8,46
5,52
Interest and investment income
-
-
24,63 m
-
Interest expense
-591,00 k
-815,00 k
-840,00 k
-364,00 k
Net interest expenses
-591,00 k
-815,00 k
23,79 m
-364,00 k
Depreciation and amortization charges
183,92 m
187,47 m
195,44 m
181,00 m
EBITDA
881,84 m
933,85 m
1,28 mjd
824,23 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme